-
-
-
-
-
-
-
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus
-
-
-
-
-
-
-
ImmunityBio (IBRX) Provides Update on BLA for N-803
-
-
-
-
-
-
-
CytRx Comments on Fiscal Year 2020 Results and Highlights Strategic Progress
15,464 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

